Bayer receives FDA approval for Xarelto ® 10 mg once daily for the extended treatment of venous thromboembolism (for specialized target groups only)

Rivaroxaban (Xarelto ®) 10 mg once daily significantly reduces the risk of recurrent venous thromboembolism compared with aspirin 100 mg once daily following at least six months of standard anticoagulation therapy / FDA approval based on data from the EINSTEIN CHOICE study
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news